Of those, uridine diphospho-glucuronosyltransferase 2B17 (UGT2B17) expression was identified as a novel molecular marker for CLL progression in two independent CLL cohorts (8, 9). The gene discussed is UGT2B17; the disease is B-cell chronic lymphocytic leukemia.